AU2013219242C1 - Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer - Google Patents

Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Info

Publication number
AU2013219242C1
AU2013219242C1 AU2013219242A AU2013219242A AU2013219242C1 AU 2013219242 C1 AU2013219242 C1 AU 2013219242C1 AU 2013219242 A AU2013219242 A AU 2013219242A AU 2013219242 A AU2013219242 A AU 2013219242A AU 2013219242 C1 AU2013219242 C1 AU 2013219242C1
Authority
AU
Australia
Prior art keywords
methods
naphthyridine
pyrrolidinyl
methylamino
thiazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013219242A
Other versions
AU2013219242A1 (en
AU2013219242B2 (en
Inventor
Daniel C. Adelman
Michael Arkin
Jennifer Hyde
Jeffrey A. Silverman
Duncan Walker
Jasmin Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006287149A external-priority patent/AU2006287149B2/en
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Priority to AU2013219242A priority Critical patent/AU2013219242C1/en
Publication of AU2013219242A1 publication Critical patent/AU2013219242A1/en
Application granted granted Critical
Publication of AU2013219242B2 publication Critical patent/AU2013219242B2/en
Priority to AU2016210657A priority patent/AU2016210657A1/en
Publication of AU2013219242C1 publication Critical patent/AU2013219242C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Abstract Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4 dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-l-(2-thiazolyl)-1,8 naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
AU2013219242A 2005-09-02 2013-08-23 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer Ceased AU2013219242C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013219242A AU2013219242C1 (en) 2005-09-02 2013-08-23 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2016210657A AU2016210657A1 (en) 2005-09-02 2016-08-03 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/218,653 2005-09-02
US11/218,387 2005-09-02
US60/789,093 2006-04-03
US60/788,927 2006-04-03
US60/810,285 2006-06-01
AU2006287149A AU2006287149B2 (en) 2005-09-02 2006-09-05 Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242A AU2013219242C1 (en) 2005-09-02 2013-08-23 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2006287149A Division AU2006287149B2 (en) 2005-09-02 2006-09-05 Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016210657A Division AU2016210657A1 (en) 2005-09-02 2016-08-03 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Publications (3)

Publication Number Publication Date
AU2013219242A1 AU2013219242A1 (en) 2013-09-12
AU2013219242B2 AU2013219242B2 (en) 2016-05-19
AU2013219242C1 true AU2013219242C1 (en) 2016-09-22

Family

ID=49115738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013219242A Ceased AU2013219242C1 (en) 2005-09-02 2013-08-23 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Country Status (1)

Country Link
AU (1) AU2013219242C1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817669A (en) * 1994-06-14 1998-10-06 Dainippon Pharmaceutical Co., Ltd. Compounds, processes for the preparation thereof and anti-tumor agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817669A (en) * 1994-06-14 1998-10-06 Dainippon Pharmaceutical Co., Ltd. Compounds, processes for the preparation thereof and anti-tumor agents

Also Published As

Publication number Publication date
AU2013219242A1 (en) 2013-09-12
AU2013219242B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
WO2008016702A3 (en) Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
WO2009075841A3 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
IL248049A0 (en) Sns-595 and methods of using the same
IL244727A0 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
TW200640908A (en) Chemical compounds
WO2007041637A3 (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
IL229136A0 (en) Mek inhibitors and methods of their use
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MX2010003868A (en) Chiral cis-imidazolines.
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
TW200510392A (en) Chemical compounds
TW200505452A (en) Chemical compounds
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
MX2010004350A (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylam ino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-c arboxylic acid in combination therapy.
NZ594829A (en) Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
AU2013219242C1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
UA90264C2 (en) Tri(cyclo) substituted amide compounds, pharmaceutical composition, methods for the treatment and prophylactic, process for the preparation of compound

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAY 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAY 2016

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired